Adamantyl pyran-4-one derivatives and their in vitro antiproliferative activity
- 31 Downloads
Pyran-4-one (maltol, kojic acid and chlorokojic acid 1) esters of adamantan-1-ylacetic acid were prepared through efficient synthetic routes in good yields and evaluated for their in vitro antiproliferative activity on four cancer cell lines: K562 (chronic myelogenous leukemia), HeLa (cervical cancer), Caco-2 (colorectal adenocarcinoma) and NCI-H358 (bronchioalveolar carcinoma). The results indicate that the presence and the position of the adamantyl acyl group or chlorine atom are the necessary requirement for antitumor activity of pyranone systems. Derivatives of kojic acid with either free (compounds 1 and 8) or acylated 5-OH group (compounds 2 and 9) have shown good-to-moderate activity (IC50 values ranging from 13.1 to 43.0 μM) on all cell lines. Adamantyl kojic acid derivative 5 with a free OH group on the position 2 showed activity only on the K562 cell line. It seems that removal of halogen or adamantyl unit from position 2 elicits antileukemic activity, as observed in compound 5. The positive influence of the adamantyl unit was also observed on a 3-OH acylated derivative of maltol I which was also selectively active on the same cell line. 5-O-benzylated adamantyl compounds 6 and 7 and unmodified starting pyranones were found to be inactive. Antibacterial activity of compounds was also evaluated on S. aureus ATCC 13709, M. catarrhalis ATCC 23246, E. faecalis ATCC29212 and E. coli TolC-Tn10, but no activity was observed (MIC values 128–256 µg/mL).
KeywordsKojic acid Maltol Adamantyl Antiproliferation Cancer
We wish to thank kindly Dr Hana Čipčić Paljetak and Dr Donatella Verbanac from the School of Medicine, University of Zagreb, for investigating the antibacterial activity of compounds. We would also like to thank the Croatian Science Foundation for support of this work (Project IP-2014-09-7899).
Compliance with ethical standards
Conflict of interest
We wish to confirm that there are no conflicts of interest associated with this publication.
- 1.Brtko J, Rondahl L, Ficková M, Hudecová D, Eybl V, Uher M (2004) Kojic acid and its derivatives: history and present state of art. Cent Eur J Public Health 12:S16–S18Google Scholar
- 2.Gonçalez ML, Marcussi DG, Fioramonti Calixto GM, Corrêa MA, Chorilli M (2015) Structural characterization and in vitro antioxidant activity of kojic dipalmitate loaded W/O/W multiple emulsions intended for skin disorders. Biomed Res Int 2015:1–8. https://doi.org/10.1155/2015/304591 CrossRefGoogle Scholar
- 3.Piršelová K, Baláž Š, Ujhelyová R, Šturdík E, Veverka M, Uher M, Brtko J (1996) Quantitative structure-time-activity relationships (QSTAR): growth inhibition of Escherichia coli by nonionizable kojic acid derivatives. Quant Struct-Act Relat 15:87–93. https://doi.org/10.1002/qsar.19960150202 CrossRefGoogle Scholar
- 4.Emami S, Ghafouri E, Faramarzi MA, Samadi N, Irannejad H, Foroumadi A (2013) Mannich bases of 7-piperazinylquinolones and kojic acid derivatives: synthesis, in vitro antibacterial activity and in silico study. Eur J Med Chem 68:185–191. https://doi.org/10.1016/j.ejmech.2013.07.032 CrossRefGoogle Scholar
- 7.Fickova M, Pravdova E, Rondhal L, Uher M, Brtko J (2008) In vitro antiproliferative and cytotoxic activities of novel kojic acid derivatives: 5-benzyloxy-2-selenocyanatomethyl - and 5-methoxy-2-selenocyanatomethyl-4-pyranone. J Appl Toxicol 28:554–559. https://doi.org/10.1002/jat.1300 CrossRefGoogle Scholar
- 10.Rho HS, Goh M, Lee J, Ahn SM, Yeon J, Yoo DS, Kim DH, Kim HG, Cho JY (2011) Ester derivatives of kojic acid and polyphenols containing adamantane moiety with tyrosinase inhibitory and anti-inflammatory properties. Bull Korean Chem Soc 32:1411–1414. https://doi.org/10.5012/bkcs.2011.32.4.1411 CrossRefGoogle Scholar
- 11.Yellamma K, Jyothi P (2017) In silico approach for validation of maltol derivatives as acetylcholinesterase inhibitors. Int J Pharm Sci Rev Res 42(1):300–306Google Scholar
- 13.Aytemir MD, Karakaya G (2012) Kojic acid derivatives. In: Ekinci D (ed) Medicinal chemistry and drug design. InTechOpen, pp 1–26. https://doi.org/10.5772/2457
- 22.Aerts J, Vandenbroucke RE, Dera R, Balusu S, Van Wonterghem E, Moons L, Libert C, Dehaen W, Arckens L (2015) Synthesis and validation of a hydroxypyrone-based, potent, and specific matrix metalloproteinase-12 inhibitor with anti-inflammatory activity in vitro and in vivo. Mediat Inflamm 2015:1–9. https://doi.org/10.1155/2015/510679 CrossRefGoogle Scholar
- 26.Campbell AL, Miyano M (1989) Kojic acid ether-ester derivatives. US Patent Number 4,812,474Google Scholar
- 27.Jay JM, Rivers GM (1984) Antimicrobial activity of some food flavoring compounds. J Food Saf 6(2):129–139. https://doi.org/10.1111/j.1745-4565.1984.tb00609.x CrossRefGoogle Scholar
- 30.Virtual Computational Chemistry Laboratory. http://www.vcclab.org/lab/alogps/. Accessed 6 Feb 2019
- 32.Supek F, Šumanovac Ramljak T, Marjanović M, Buljubašić M, Kragol G, Ilić N, Šmuc T, Zahradka D, Mlinarić-Majerski K, Kralj M (2011) Could log P be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns. Eur J Med Chem 46:3444–3544. https://doi.org/10.1016/j.ejmech.2011.05.009 CrossRefGoogle Scholar